ArticleNano-micro letters2026
A Universal Bio-Hybrid Nanoparticle Backpack Platform Endows Stem Cells with Microenvironmental Resilience and Sustained Paracrine Signaling.
Article in Nano-micro letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The therapeutic potential of mesenchymal stem cells (MSCs) in regenerative medicine is frequently thwarted by hostile post-injury microenvironments characterized by oxidative stress, inflammation, and rapid clearance, which compromise cell survival and paracrine efficacy. Herein, we establish a universal bio-hybrid "stem cell backpack" platform designed to fundamentally overcome these bottlenecks through precise surface interface engineering. By tethering drug-loaded mesoporous silica nanoparticles onto the MSCs membrane via mild, biocompatible click chemistry, we create a programmable nanotherapeutic depot that endows host cells with dual, synergistic capabilities: (1) robust scavenging of reactive oxygen species (ROS) to ensure cellular resilience and (2) sustained, localized release of regenerative factors to amplify paracrine signaling. Using corneal chemical injury as a rigorous proof-of-concept model, this platform demonstrated unprecedented regenerative potency. The engineered cells markedly outperformed conventional therapies by simultaneously suppressing inflammatory cascades, preventing fibrosis and neovascularization, and orchestrating multi-lineage regeneration, including epithelial restoration, nerve reinnervation, and limbal stem cell reactivation. Quantitatively, this approach achieved a 63.6% enhancement in transparency restoration and a 76.9% greater reduction in tissue defects compared to cell monotherapy. Crucially, the modular design of this backpack system allows for the interchangeable loading of diverse therapeutics, extending its applicability beyond ophthalmology to other tissues facing similar microenvironmental challenges. This work presents a transformative paradigm in nanomedicine, shifting the focus from passive cell delivery to active microenvironmental modulation, thereby offering a versatile and scalable strategy for next-generation regenerative therapies across diverse clinical indications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.